Axsome Therapeutics, Inc (AXSM)

Etorro trading 970x250

About Axsome Therapeutics, Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer’s disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York. Address: 22 Cortlandt Street, New York, NY, United States, 10007

Axsome Therapeutics, Inc News and around…

Latest news about Axsome Therapeutics, Inc (AXSM) common stock and company :

3 Biotech Stocks That Can Double Your Money, According to Wall Street
25 Nov, 2021 FinancialContent

All three of these stocks could rise over 100% once stock-market sentiment falls in line with the opinions of investment-bank analysts.

Insiders who bought into Axsome Therapeutics, Inc. (NASDAQ:AXSM) earlier this year might wish they'd invested more as stock gained 9.8%
25 Nov, 2021 Yahoo! Finance

Last week, Axsome Therapeutics, Inc. ( NASDAQ:AXSM ) insiders, who had purchased shares in the previous 12 months were...

2 Top Biotech Stocks Ready for a Bull Run
24 Nov, 2021 FinancialContent

Both of these companies have potential catalysts on the way.

Analysts Expect 13% Upside For VBR
23 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Value ETF (VBR), we found that the implied analyst target price for the ETF based upon its underlying holdings is $207.07 per unit.

Bargain Hunters Take Note: Insider Cluster-Buying At AXSM
22 Nov, 2021 FinancialContent

A particularly strong insider buying signal is what we call a "cluster-buy" where three or more different insiders make open market purchases within a short period of one another. At Axsome Therapeutics Inc (AXSM), 3 different insiders purchased 5,685 shares at an average price of $34.79/share, for a total of $197,778, with the most recent purchase on November 18, 2021.

Noteworthy Tuesday Option Activity: CMP, AXSM, HYFM
16 Nov, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Compass Minerals International Inc (CMP), where a total of 2,568 contracts have traded so far, representing approximately 256,800 underlying shares. That amounts to about 121% of CMP's average daily trading volume over the past month of 212,150 shares..

Is Compass Pathways Stock a Once-in-a-Lifetime Bargain?
11 Nov, 2021 FinancialContent

Investors might want to give this psychedelic stock another look.

How Much Upside is Left in Axsome (AXSM)? Wall Street Analysts Think 144%
10 Nov, 2021 Yahoo! Finance

The average of price targets set by Wall Street analysts indicates a potential upside of 143.7% in Axsome (AXSM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Axsome (AXSM) Q3 Earnings Top, Pre-Launch Activities Continue
09 Nov, 2021 Yahoo! Finance

Axsome Therapeutics (AXSM) reports a narrower-than-expected Q3 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.

Axsome Therapeutics, inc (AXSM) Q3 2021 Earnings Call Transcript
08 Nov, 2021 FinancialContent

AXSM earnings call for the period ending September 30, 2021.

Notable Monday Option Activity: AXSM, DKNG, NDLS
08 Nov, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Axsome Therapeutics Inc (AXSM), where a total volume of 8,798 contracts has been traded thus far today, a contract volume which is representative of approximately 879,800 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 109.3% of AXSM's average daily trading volume over the past month, of 804,745 shares..

Why Axsome Therapeutics Stock Is Rising Today
08 Nov, 2021 FinancialContent

The company provided its third-quarter update.

Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
08 Nov, 2021 Yahoo! Finance

Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2021. “Over the past several months we have continued to advance our differentiated late-stage CNS product candidates aimed at meaningfully improving the lives of pa

2 Growth Stocks That Could Deliver 1,000% Returns
31 Oct, 2021 FinancialContent

These two low-priced biotech stocks could produce life-changing returns for early shareholders.

Noteworthy Tuesday Option Activity: AXSM, PTON, TPX
26 Oct, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Axsome Therapeutics Inc (AXSM), where a total volume of 7,780 contracts has been traded thus far today, a contract volume which is representative of approximately 778,000 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 82.2% of AXSM's average daily trading volume over the past month, of 945,985 shares..

VTWG's Holdings Imply 23% Gain Potential
21 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $270.75 per unit.

Axsome Therapeutics to Report Third Quarter 2021 Financial Results on November 8, 2021
20 Oct, 2021 Yahoo! Finance

Axsome to host conference call and webcast on Monday, November 8, 2021 at 8:00 AM Eastern Time NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter of 2021 on Monday, November 8, 2021 before the opening of the U.S. financial markets. Axsome’s management team will host a

Axsome Therapeutics Expands Term Loan Facility with Hercules Capital to $300 Million
18 Oct, 2021 Yahoo! Finance

$100 million now available upon the potential FDA approval of AXS-05 NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that its existing term loan facility agreement with Hercules Capital, Inc. (NYSE: HTGC), has been amended to increase the size of the facility to $300 million, and the amount immediately available upon U.S. Food

2 Biotech Stocks Poised for Jaw-Dropping Growth
17 Oct, 2021 FinancialContent

These two tiny drugmakers could make early shareholders wealthy.

3 Biotech Stocks That Could Rise 90% or More, According to Wall Street
17 Oct, 2021 FinancialContent

These stocks are expected to put up big gains in a short amount of time.

First Week of AXSM June 2022 Options Trading
15 Oct, 2021 FinancialContent

Investors in Axsome Therapeutics Inc (AXSM) saw new options become available this week, for the June 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 245 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Why Axsome Therapeutics Stock Rocketed Higher This Week
15 Oct, 2021 FinancialContent

Optimism among investors is growing for the possible approval of the biotech's MDD drug.

1 Beaten-Down Stock With 10X Potential
14 Oct, 2021 FinancialContent

This biotech is down, but it isn't out just yet.

Notable Wednesday Option Activity: NET, AXSM, PANW
13 Oct, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in CloudFlare Inc (NET), where a total of 41,131 contracts have traded so far, representing approximately 4.1 million underlying shares. That amounts to about 99.7% of NET's average daily trading volume over the past month of 4.1 million shares..

45 Biggest Movers From Yesterday
13 Oct, 2021 FinancialContent

Gainers ESSTech Inc (NYSE: GWH) shares surged 128.4% to close at $23.80 onTuesday. ESS Inc, the Bill Gates-backed battery maker ...

Why Axsome Therapeutics Stock Caught Fire in September
06 Oct, 2021 FinancialContent

This beaten-down biotech regained some lost ground last month.

SHAREHOLDER ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses Over $100K to Inquire About Class Action Investigation - AXSM
30 Sep, 2021 Yahoo! Finance

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM) resulting from allegations that Axsome may have issued materially misleading business information to the investing public.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shareholder Notice: Investigation over Possible Wrongdoing
29 Sep, 2021 FinancialContent

San Diego, CA -- (SBWIRE) -- 09/29/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Axsome Therapeutics, Inc.

2 Best Biotech Stocks to Buy Right Now
25 Sep, 2021 FinancialContent

Aurinia Pharmaceuticals and Axsome Therapeutics are two names that growth investors should have on their radars right now.

Do Options Traders Know Something About Axsome (AXSM) Stock We Don't?
24 Sep, 2021 Yahoo! Finance

Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.

Axsome Therapeutics, Inc (AXSM) is a NASDAQ Common Stock listed in , ,

970x250